For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many
cancers, including∼ 12% of acute myeloid leukemia (AML). In preclinical models these …

PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …

Purpose Patients with acute myeloid leukemia (AML) who are in morphologic complete
remission are typically considered separately from patients with active disease (ie,≥ 5 …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation
(allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

The past 40 years have witnessed major advances in defining the cytogenetic aberrations,
mutational landscape, epigenetic profiles, and expression changes underlying …